GST 2.0: Pharmaceutical Industry Impact, Changes & Challenges

GST 2.0: Transforming India’s Pharmaceutical Landscape – A Comprehensive Analysis of Changes and Challenges

The implementation of GST 2.0 marks a pivotal moment for India’s pharmaceutical industry, introducing significant tax rate reductions that promise enhanced healthcare affordability while simultaneously creating complex operational challenges for businesses. This comprehensive analysis examines the key changes, quantifies their impact, and provides strategic guidance for industry stakeholders navigating this transformation.

Indian Pharmaceutical Industry – Introduction

The Indian pharmaceutical industry is experiencing significant growth, with projections indicating a substantial increase in market size over the coming years. According to the India Brand Equity Foundation (IBEF), the market size of the Indian pharmaceuticals industry is expected to reach US$ 65 billion by 2024, approximately US$ 130 billion by 2030, and US$ 450 billion by 2047. This growth is driven by factors such as increasing domestic demand, a strong export market, and advancements in biotechnology and manufacturing capabilities.

The pharmaceutical sector’s expansion is further supported by India’s position as a global leader in generic drug production, contributing to over 20% of global generic drug exports. The country is also the largest vaccine supplier worldwide, accounting for more than 60% of all vaccines manufactured globally. Additionally, the sector’s resilience is evident, with reports indicating an 8.1% year-on-year growth in August, reflecting steady momentum across various therapeutic categories.

As the industry continues to evolve, embracing innovation, enhancing regulatory compliance, and expanding global partnerships will be crucial for sustaining growth and maintaining competitiveness in the global pharmaceutical market.

The new tax framework, effective September 22, 2025, represents the government’s commitment to making healthcare more accessible while addressing the structural complexities of pharmaceutical taxation. This article provides a detailed examination of the changes, challenges, and strategic implications for industry stakeholders.

Key Changes Under GST 2.0 – Pharmaceutical Industry

1. Life-Saving Drugs: Complete Tax Exemption

The most significant change under GST 2.0 is the complete elimination of GST on life-saving drugs:

• 33 life-saving drugspreviously taxed at 12% are now completely exempt
• 3 additional life-saving drugsfor cancer and rare diseases reduced from 5% to 0%
• This exemption covers medications for critical conditions including diabetes, hypertension, cardiovascular diseases, and oncology treatments

Impact Analysis: A life-saving cardiac medication previously priced at ₹1,120 (including 12% GST) will now be available at ₹1,000, representing a direct saving of ₹120 per unit for patients.

2. General Pharmaceutical Products: Substantial Rate Reduction

• All other drugs and medicines: GST reduced from 12% to 5%
• Indian System of Medicines (ISM): Rate reduction from 12% to 5%
• This includes Ayurvedic, Unani, Siddha, and Homeopathic medicines, promoting traditional healthcare systems

Financial Impact: A general medicine previously priced at ₹112 will now cost ₹105, providing consumers with a ₹7 saving per unit while maintaining manufacturer margins.

3. Medical Equipment and Devices: Enhanced Accessibility

The GST 2.0 framework extends benefits to medical infrastructure:

Major Medical Apparatus:

• GST reduction from 18% to 5%on medical, surgical, dental, and veterinary equipment
• Includes diagnostic machines, surgical instruments, and analytical equipment

Medical Supplies and Equipment:

• Rate reduction from 12% to 5%on essential supplies including:
  • Surgical consumables (wadding, gauze, bandages)
  • Diagnostic kits and reagents
  • Blood glucose monitoring systems
  • Medical devices and implants

Quantified Benefits: Consumer Price Impact Analysis

 GST 2.0  Impact on Pharma Packaging Materials:

The GST 2.0 revisions, effective September 22, 2025, significantly reduce tax rates on select pharma packaging materials, impacting costs and margins across the pharmaceutical supply chain.

Key Takeaways:

• Cost reduction mainly for:paper, cardboard, wooden crates, textile sacks.
• No tax relief for:plastic drums, PET bottles, metal strips, foil, glass, thermocol—critical for specialty or temperature-sensitive drugs.
• Strategic implication:Companies can optimize packaging mix to leverage GST savings while maintaining quality and regulatory compliance.

Pharma Job Work: Strengthening Pharma Outsourcing: Boosting Competitiveness & Cost Efficiency

The reduction of GST on job work services for goods under Chapter 30 (pharmaceuticals) from 12% to 5% will directly lower outsourcing and contract manufacturing costs. Since over 35–40% of Indian pharma production involves job work, this move reduces compliance burden, improves working capital efficiency, and enhances cost competitiveness. The benefit is particularly significant for SMEs and contract manufacturers, who operate on thin margins and high dependency on third-party services.

Critical Challenges and Industry Impact

1. Inverted Duty Structure (IDS): The Primary Challenge

Understanding the Problem: The most significant challenge facing pharmaceutical manufacturers is the intensification of the Inverted Duty Structure, where input costs carry higher GST rates than finished products.

In pharma, an Inverted Duty Structure (IDS) arises when inputs (APIs, KSMs, plastic packaging) attract 18% GST, while finished drugs are taxed at 0–5%. Value addition varies depending on business model, integration level, and product type, but typically falls in the 70–80% range for formulations and 50–60% for API manufacturing. Most formulation players stay near or below the break-even (27.8% input share), but API-heavy firms face ITC accumulation. Though refunds are permitted, companies struggle with blocked working capital, delayed processing, and denial of certain input credits, leading to sustained cash-flow pressures.

Current Scenario:

• Active Pharmaceutical Ingredients (APIs): Continue to be taxed at 18%
• Key Starting Materials (KSMs): Remain at 18%
• Finished drugs: Now taxed at 5%or 0%

IDS Impact Calculation Framework:

ITC Accumulation = (Input Tax Rate – Output Tax Rate) × Input Value Proportion

Example:

Assume

• API input cost: ₹70 per unit (18% GST = ₹12.60)
• Excipients cost: ₹20 per unit (18% GST = ₹3.60)
• Total input tax: ₹16.20
• Finished product selling price: ₹200
• Output tax (5%): ₹10
• Net ITC accumulation: ₹16.20 – ₹10  = ₹6.20 per unit

Break-Even Analysis for Inverted Duty Structure (Output @ 5%, Input @ 18%)

Understanding the break-even point is crucial for pharmaceutical manufacturers to assess their ITC accumulation risk and cash flow impact under GST 2.0.

Break-Even Formula:

Break-Even Point: Input Tax Rate × Input Share = Output Tax Rate

Assume Input Tax Rate = 18 %

Output Tax Rate = 5%

@ Break-Even Point: 18% × Input Share = 5%

Input Share = 5% ÷ 18% = 27.8% @ Break-Even Point.

Pharma Manufacturing – Inputs, Value Addition & IDS Impact

Key Insights from Break-Even Analysis:

1. Break-Even Point: Companies with input share ≤27.8% of selling price will not face ITC accumulation

2. Favorable Zone: High value-addition companies (>72.2%) benefit from positive cash flow

3. Risk Zone: Companies with input share >30% face increasing ITC accumulation challenges

4. Critical Threshold: Input share of 40% results in 2.2% ITC accumulation on sales value

Inverted Duty Structure : Refund Challenges – Blocked Credits and Cash Flow Strain

Under GST, pharmaceutical companies can legally claim refunds of unutilized Input Tax Credit (ITC) arising from an Inverted Duty Structure (IDS), but only for input goods, while capital goods and most services are excluded. This creates a structural imbalance, as high GST on APIs, KSMs, and packaging materials contrasts with lower GST on finished drugs, leading to ITC accumulation.

In practice, claiming these refunds is complex and time-consuming, involving heavy documentation, frequent rejections, and delayed processing. Even though refunds are legally allowed, temporary working capital remains blocked, often accounting for 3–5% of turnover for API-heavy manufacturers.

As a result, IDS poses a persistent cash flow challenge, making it a structural constraint rather than an immediate relief, especially for companies heavily reliant on imported or high-cost inputs. Effective planning, ITC tracking, and supply chain optimization are essential to mitigate the financial impact.

2. Challenges with Existing Inventory

The main challenge for manufacturers lies in managing goods produced, priced, and taxed under old GST rates, including stock in factories, goods in transit, and products already with distributors and retailers.

Industry Concerns: Pharma associations pointed out that recalling or re-labelling products with old MRPs, as mandated by the Department of Consumer Affairs (DoCA) in its letter dated September 9, 2025 (I-10/14/2020-W&M), was impractical and costly. Responding to these concerns, the government has revised the compliance norms to provide operational relief.

Revised Compliance Guidelines (DoCA Notification – Sept 18, 2025)

• No mandatory re-labelling:Unsold pre-packaged goods made before Sept 22, 2025 need not carry revised price stickers; stickers remain voluntary.
• Waiver of newspaper ads:Companies are no longer required to publish revised prices in newspapers. Instead, they must circulate price notifications to wholesalers, retailers, and Legal Metrology authorities.
• Extended use of old packaging:Wrappers/cartons with old MRPs can be used till March 31, 2026 or until stocks last, provided corrected prices are stamped, stickered, or digitally printed.

The government has eased compliance to avoid disruption, allowing continued sale of goods with old MRPs and use of existing packaging, while ensuring price correction flows through the supply chain via revised price lists.

NPPA Directive on MRP Revision (Sept 12, 2025):

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, issued an Office Memorandum on September 12, 2025, directing pharma companies to revise the Maximum Retail Price (MRP) of drugs and medical devices in line with the GST rate reduction effective September 22, 2025.

Manufacturers are required to issue revised price lists to dealers and retailers to reflect the new GST rates and MRPs. However, recalling, re-labelling, or re-stickering existing stock is not mandatory, provided compliance with revised pricing can be ensured at the retailer level.

Revised Price Lists: Manufacturers/marketing companies must issue revised or supplementary price lists to:

• Dealers and retailers for consumer display
• State Drug Controllers
• Central/State Government authorities

Coverage: This applies to all drugs, formulations, and medical devices affected by the GST rate changes.

Industry Relief: The measure reduces operational burden and costs, allowing smooth market transition while maintaining regulatory compliance and business continuity.

3. GST 2.0 Impact on Imported Pharmaceutical Inputs in Transit

For imported goods in transit that have not yet cleared customs, GST 2.0 applies IGST based on the Bill of Entry (BoE) filed. If the BoE is filed before the effective date of September 22, 2025, the old IGST rate applies; if filed on or after September 22, 2025, the revised GST 2.0 rates are applicable. Consequently, imported inputs may attract higher or lower IGST depending on the BoE filing date, which directly affects ITC accumulation and working capital planning for manufacturers. Accurate tracking of BoE dates is therefore critical for compliance and cash flow management.

4. Operational and Financial Challenges for Pharma under GST 2.0

The GST 2.0 rate changes, while reducing taxes on finished drugs, create multiple operational and financial challenges for pharmaceutical companies:

• ERP and Accounting Updates:Systems must be reconfigured for new tax codes, pricing logic, and master data across thousands of SKUs (Stock Keeping Unit):.
• Credit Notes & Book Adjustments:Manufacturers must issue credit notes to distributors and retailers for reduced GST rates, requiring meticulous reconciliation.
• Invoicing Complexity:Invoices must reflect revised GST rates, transitional credits, and adjustments for prior sales, increasing administrative workload.
• Inventory Management:Existing stock with old MRP or GST rates, and packaging materials, need careful tracking to ensure compliance.
• Pricing & MRP Compliance:Revising MRPs across distributors and retailers without disrupting supply chains is complex.
• Financial Planning:Reduced GST outflows impact state-level incentives and budgetary support schemes, requiring recalculated cash flow projections.
• Operational Coordination:Integration across procurement, production, finance, and sales is necessary to prevent misalignment in taxation and billing.

Key Insight: These challenges require strategic planning, robust IT systems, and proactive compliance to maintain cash flow, operational efficiency, and regulatory adherence while leveraging GST 2.0 benefits.

5. Retail Dynamics – Reduced Margins Limit Price Pass-Through to Consumers

During the transition, distributors and retailers are unlikely to reduce MRPs, as their existing stock was purchased at higher GST rates. Although manufacturers are required to issue credit notes to distributors and retailers to compensate for the reduced GST, this process is complex and often delayed. If credit notes are not promptly processed, distributors and retailers may safeguard their margins, making it unlikely that the benefit of reduced GST will reach end consumers. Additionally, previously offered discounts or promotional schemes may be limited or reduced, and enforcing revised MRPs across India’s large and largely unorganized retail sector remains practically very difficult.

6. Reduced Tax Outflows – Impacts Pharma Incentives:

Pharma companies claiming state-level incentives (based on net SGST paid in cash) or the Budgetary Support Scheme (58% of IGST or 29% of CGST paid in cash) may experience reduced incentive amounts under GST 2.0. Incentive amounts are proportional to actual GST outflow. The lower GST outflows resulting from reduced rates directly decrease the base on which these incentives are calculated, impacting cash benefits for eligible companies.

 Reduced GST outflows directly reduce the incentive base, causing an estimated 55–60% drop in cash benefits for eligible pharma companies.

Note: Not all sales may be eligible for incentives. Some products might have already been exempt or taxed differently, slightly reducing the overall impact.

Conclusion

GST 2.0 marks a landmark reform for the pharmaceutical sector, with significant GST reductions—complete exemption for life-saving drugs and lower rates for general medicines, medical devices, and packaging materials. These measures aim to improve healthcare affordability, enhance access to critical medicines, and reduce operational costs for manufacturers.

However, the reform also introduces operational and financial challenges, including inverted duty structure (high GST on APIs vs low GST on finished goods), ITC accumulation, working capital strain, and complexity in updating ERP systems, pricing, and inventory. Distributors and retailers may not immediately pass on the benefits, limiting short-term impact on consumers. Incentive flows based on GST outflows are also reduced by ~55–60%, affecting cash benefits for eligible companies.

Government relief measures—including no mandatory recall or re-labelling of existing stock, flexibility in packaging use, and simplified price notifications—help mitigate transition risks. For companies, proactive compliance, supply chain optimization, and financial planning are critical. Firms that strategically address these challenges while leveraging tax reductions will improve accessibility, maintain sustainable operations, and emerge as leaders in India’s transformed pharmaceutical landscape.